Atossa Genetics Inc. (ATOS) Trading at $2.21 Reached All-Time Low

June 29, 2018 - By Ashley Bratcher

Atossa Genetics Inc. (NASDAQ:ATOS) Corporate Logo

Atossa Genetics Inc. (NASDAQ:ATOS) touched all time low on Jun, 29 touching $2.21. Our target is $2.06. Barchart.com announced it. The company has $6.22 million market cap. The company’s valuation will be $435,470 less at $2.06 target.

The stock decreased 3.07% or $0.07 during the last trading session, reaching $2.21.Currently Atossa Genetics Inc. is downtrending after 41.40% change in last June 29, 2017. ATOS has also 123,725 shares volume. The stock underperformed the S&P500 by 53.97%.

On August, 13 Atossa Genetics Inc. (NASDAQ:ATOS)’s earnings release is anticipated by WallStreet, as reported by Faxor. Analysts predict $-0.74 earnings per share, which is $6.94 up or 90.36 % from 2017’s $-7.68 earnings per share. After $-0.71 EPS report previous quarter, Wall Street now sees 4.23 % negative EPS growth of Atossa Genetics Inc..

Atossa Genetics Inc. (NASDAQ:ATOS) Ratings Coverage

In total 2 analysts cover Atossa Genetics (NASDAQ:ATOS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:ATOS)’s analyst reports since January 26, 2018 according to StockzIntelligence Inc. On Friday, January 26 Maxim Group initiated Atossa Genetics Inc. (NASDAQ:ATOS) rating. Maxim Group has “Buy” rating and $2.0 target.

For more Atossa Genetics Inc. (NASDAQ:ATOS) news brought out recently go to: Benzinga.com, Benzinga.com, Benzinga.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” brought out on June 29, 2018, “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” on June 19, 2018, “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” with a publish date: June 15, 2018, “Atossa Genetics (ATOS) Announces Opening of Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast …” and the last “Your Daily Pharma Scoop: Reata Begins New Trial, CytoDyn Amends Protocol, Argenx Reports Positive Data” with publication date: June 22, 2018.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States.The firm is worth $6.22 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions.Last it reported negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: